Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.72M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerReviva Pharmaceuticals Holdings, Inc. (RVPH) trades at $0.284. Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Market cap: $3.72M, Sector: Healthcare.
Price as of · Last analyzed: May 10, 2026RVPH stock analysis for 2026: The stored analyst price target for Reviva Pharmaceuticals Holdings, Inc. is $95.00; its date is unknown, so no upside or downside is derived from it against the current price of $0.28. Key factors: analyst coverage, company fundamentals.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) Healthcare & Pipeline Overview
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on next-generation therapeutics for central nervous system, respiratory, and inflammatory diseases. Their lead candidate, RP5063, targets schizophrenia and is in Phase III trials, positioning the company in the competitive biotechnology landscape with a focus on unmet medical needs.
What Is the Investment Thesis for RVPH?
Reviva Pharmaceuticals presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful completion of Phase III trials for RP5063 in schizophrenia, with potential FDA approval and subsequent commercialization. Positive data from ongoing trials could significantly increase the company's valuation. Further, the advancement of RP1208 into clinical trials for depression and obesity represents a secondary growth catalyst. However, the company's limited market capitalization and reliance on future funding introduce substantial financial risk. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's cash runway.
Based on FMP financials and quantitative analysis
RVPH Key Highlights
RP5063 is in Phase III clinical trials for schizophrenia, representing a near-term value inflection point.
- RP5063 has completed Phase I clinical trials for multiple indications, showcasing its potential versatility.
- RP1208 is in pre-clinical development for depression and obesity, expanding the company's pipeline.
- The company has a small team of 14 employees, indicating a lean operational structure.
- Reviva Pharmaceuticals focuses on addressing unmet medical needs in CNS, respiratory, and other therapeutic areas.
Who Are RVPH's Competitors?
RVPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
| INDP Indaptus Therapeutics, Inc. | $3.13 | -4.86% | $481M | 60 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.07 | -2.26% | $540M | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RVPH's Key Strengths?
Promising lead product candidate (RP5063) in Phase III trials.
- Diverse pipeline targeting multiple CNS disorders.
- Experienced management team with pharmaceutical expertise.
What Are RVPH's Weaknesses?
Limited financial resources and reliance on future funding.
- Small team size and limited infrastructure.
- High risk associated with clinical-stage drug development.
What Could Drive RVPH Stock Higher?
Release of Phase III clinical trial data for RP5063 in schizophrenia.
- Initiation of clinical trials for RP1208 in depression and obesity.
- Regulatory interactions with the FDA regarding RP5063 approval.
What Are the Key Risks for RVPH?
Listing risk — at $0.284 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -14.54 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-64.4%) — the business is not currently generating profit on shareholder capital.
- Failure of RP5063 to meet primary endpoints in Phase III trials.
- Delays in clinical trial timelines or regulatory approvals.
- Competition from other companies developing CNS therapies.
- Dependence on future funding to support operations.
What Are the Growth Opportunities for RVPH?
- RP5063 Expansion into Additional Indications: RP5063 has completed Phase I clinical trials for bipolar disorder, major depressive disorder and other indications. Positive results in these additional indications could significantly broaden its market potential beyond schizophrenia.
- Advancement of RP1208: RP1208, currently in pre-clinical development for depression and obesity, represents a significant growth opportunity. The market for depression and obesity treatments is substantial, with increasing prevalence worldwide. Successful development and commercialization of RP1208 could diversify Reviva's product portfolio and revenue streams. Clinical trials are expected to begin by 2028.
- Strategic Partnerships: Reviva could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations could provide access to funding, expertise, and distribution networks, enhancing Reviva's ability to bring its therapies to market effectively. Potential partnerships could be formed by 2027.
- Geographic Expansion: While currently focused on the US market, Reviva could expand its operations to other geographic regions, such as Europe and Asia. These regions represent significant growth opportunities, particularly in countries with increasing healthcare spending and unmet medical needs. Expansion could begin by 2029 pending successful trials.
- Orphan Drug Designation: Seeking orphan drug designation for RP5063 in specific subpopulations of patients with schizophrenia or other CNS disorders could provide regulatory and financial benefits, including market exclusivity and tax incentives. This could accelerate the drug's development and commercialization, enhancing its attractiveness to investors and potential partners. This could be pursued by 2027.
What Threats Does RVPH Face?
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Patent expirations and generic drug entry.
What Are RVPH's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical data supporting efficacy and safety.
- Focus on unmet medical needs in specific therapeutic areas.
What Does RVPH Do?
Reviva Pharmaceuticals Holdings, Inc., headquartered in Cupertino, California, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies. The company focuses on addressing unmet medical needs across a range of therapeutic areas, including central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Reviva's lead product candidate, RP5063, is currently undergoing Phase III clinical trials for the treatment of schizophrenia. Additionally, RP5063 has completed Phase I clinical trials for various other conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. The company is also developing RP1208, a preclinical candidate targeting depression and obesity. Reviva's strategy centers on creating next-generation therapeutics that can offer improved efficacy and safety profiles compared to existing treatments. With a lean team of 14 employees, Reviva operates with a focus on efficient drug development and clinical advancement.
What Products and Services Does RVPH Offer?
- Discovers and develops next-generation therapeutics.
- Focuses on diseases with unmet medical needs.
- Develops treatments for central nervous system disorders.
- Creates therapies for respiratory diseases.
- Develops treatments for cardiovascular diseases.
- Creates therapies for metabolic diseases.
- Develops treatments for inflammatory diseases.
- Conducts clinical trials to evaluate drug efficacy and safety.
How Does RVPH Make Money?
- Develops pharmaceutical products through clinical trials.
- Seeks regulatory approval for commercialization.
- Out-licenses or commercializes approved drugs.
- Raises capital through equity offerings and partnerships.
What Industry Does RVPH Operate In?
Reviva Pharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for central nervous system (CNS) therapeutics, particularly schizophrenia treatments, is substantial and growing, driven by increasing prevalence and unmet needs. Competition includes established pharmaceutical giants and other emerging biotech companies developing novel therapies. Reviva's success hinges on demonstrating superior efficacy and safety compared to existing treatments and successfully navigating the regulatory approval process.
Who Are RVPH's Key Customers?
- Patients suffering from schizophrenia.
- Patients with bipolar disorder.
- Patients with major depressive disorder.
- Healthcare providers prescribing medications.
- Hospitals and clinics administering treatments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● Covered by analysts
Company Profile
Reviva Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cupertino, United States.
Financial Health
Reviva Pharmaceuticals Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.54 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Reviva Pharmaceuticals Holdings, Inc. stands at -64.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.6%, showing how much profit it generates from its asset base. A current ratio of 3.56 indicates the company holds enough short-term assets to cover its near-term obligations.
RVPH Valuation & Market Position
With a $3.72M market cap, Reviva Pharmaceuticals Holdings, Inc. sits in the micro-cap segment of the market.
Earnings Track Record
Reviva Pharmaceuticals Holdings, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 354.9% below estimates on average.
Forward Outlook
Wall Street analysts project Reviva Pharmaceuticals Holdings, Inc. revenue of about $5.0M for fiscal 2026, with EPS near $-1.16. The estimate reflects 3 contributing analysts.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 7 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
RVPH Financials
Bull Case vs Bear Case
Bull Case
- Promising lead product candidate (RP5063) in Phase III trials.
- Diverse pipeline targeting multiple CNS disorders.
- Experienced management team with pharmaceutical expertise.
- Upcoming: Release of Phase III clinical trial data for RP5063 in schizophrenia.
Bear Case
- Limited financial resources and reliance on future funding.
- Small team size and limited infrastructure.
- High risk associated with clinical-stage drug development.
- Potential: Failure of RP5063 to meet primary endpoints in Phase III trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RVPH Latest News
-
RVPH: FDA Feedback on New Formulation Imminent
Yahoo! Finance: RVPH News · Nov 17, 2026
-
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Yahoo! Finance: RVPH News · Sep 22, 2026
-
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com · Sep 22, 2026
RVPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RVPH.
Price Targets
Consensus target: $95.00
RVPH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RVPH; grades run from A+ (80-100) to F (below 30).
Latest News
RVPH: FDA Feedback on New Formulation Imminent
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
Leadership: Laxminarayan Bhat
Unknown
Therefore, a detailed biography including career history, education, and previous roles cannot be provided. Further research would be needed to gather this information.
Track Record: Information about Laxminarayan Bhat's track record is not available within the provided data. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to gather this information.
RVPH OTC Market Information
RVPH trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About RVPH (Healthcare)
Is RVPH a good stock to buy?
Stock Expert AI does not rate RVPH buy, sell or hold. Reviva Pharmaceuticals Holdings, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RVPH stock price today?
The last price recorded on this page for Reviva Pharmaceuticals Holdings, Inc. (RVPH) is $0.284, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about RVPH stock?
Analyst coverage of Reviva Pharmaceuticals Holdings, Inc. is currently unavailable based on the provided data. Therefore, a consensus rating, price target, or detailed valuation analysis cannot be provided. Monitor news sources for updated analyst ratings.
What are the key factors to evaluate for RVPH?
Evaluate RVPH on fundamentals, analyst consensus, and risk factors. RP5063 is in Phase III clinical trials for schizophrenia, representing a near-term value inflection point. Not financial advice.
How frequently does RVPH data refresh on this page?
RVPH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RVPH's recent stock price performance?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product candidate (RP5063) in Phase III trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RVPH overvalued or undervalued right now?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RVPH?
Fractional-share availability for Reviva Pharmaceuticals Holdings, Inc. (RVPH) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on limited data provided.
- Analyst ratings are unavailable.